Tivicay
Gilead’s New Drug Application for Yeztugo accepted by US FDA
The investigational once-weekly oral treatment could be the first long-acting pill for HIV prevention
ViiV Healthcare receives NICE recommendation for HIV prevention therapy
The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales
Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use
An estimated 1.2 million people in the US are currently living with the virus
Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval
More than 100 people in the US were diagnosed with HIV every day in 2023
Cultivating Interest in Infectious Disease Education at ID Week 2024
IDWeek starts tomorrow, October 16, and Medscape is bringing outcomes and education! We are excited to announce Medscape is presenting six posters that highlight the significant impact of our educational...
GSK’s ViiV shares positive head-to-head results for two-drug HIV regimen Dovato
The phase 4 trial has been comparing Dovato against Gilead’s three-drug regimen, Biktarvy
Reaching Women Where They’re At: Setting Up a Safe Space for HIV Prevention Conversations
“I always enjoyed solving problems and putting puzzles together,” says Harmony Garges, MD, CMO at ViiV Healthcare and a pediatric infectious disease specialist. “So for me, infectious disease was a...
World AIDS Day 35: Medscape’s Commitment to the Elimination of HIV through Education and Looking Towards the Future
December 1 marks the 35th year commemorating World AIDS Day, and the theme is “Remember and Commit.” While new infections have steadily declined over the last several years, HIV remains a...
Article: Could combating stigma increase the uptake of PrEP and finally end the HIV epidemic?
In this article we explore what more could be done by the pharmaceutical industry to help prevent the spread of HIV infection worldwide.
WHO calls for leaders to address the global HIV response
Its key focus is to highlight inequalities that hinder progress in the goal to end AIDS by 2030
GSK’s ViiV submits application for cabotegravir to EMA for HIV-1 prevention
Cabotegravir offers up to two months of protection from a single injection
Gilead’s latest Biktarvy data offers hope to HIV patients
The data was shared at the 30th International Congress on Drug Therapy in HIV Infection